Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 29

1.

Inhibition of the alloantibody response by CD95 ligand.

Arai H, Chan SY, Bishop DK, Nabel GJ.

Nat Med. 1997 Aug;3(8):843-8.

PMID:
9256273
2.

Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction.

Kang SM, Schneider DB, Lin Z, Hanahan D, Dichek DA, Stock PG, Baekkeskov S.

Nat Med. 1997 Jul;3(7):738-43.

PMID:
9212099
3.

The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand.

O'Connell J, O'Sullivan GC, Collins JK, Shanahan F.

J Exp Med. 1996 Sep 1;184(3):1075-82.

4.

The inhibition of pro-apoptotic ICE-like proteases enhances HIV replication.

Chinnaiyan AM, Woffendin C, Dixit VM, Nabel GJ.

Nat Med. 1997 Mar;3(3):333-7.

PMID:
9055863
5.

Antitumor effect of locally produced CD95 ligand.

Seino K, Kayagaki N, Okumura K, Yagita H.

Nat Med. 1997 Feb;3(2):165-70.

PMID:
9018234
6.

Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells--a mechanism of immune evasion?

Strand S, Hofmann WJ, Hug H, Müller M, Otto G, Strand D, Mariani SM, Stremmel W, Krammer PH, Galle PR.

Nat Med. 1996 Dec;2(12):1361-6.

PMID:
8946836
7.

Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape.

Hahne M, Rimoldi D, Schröter M, Romero P, Schreier M, French LE, Schneider P, Bornand T, Fontana A, Lienard D, Cerottini J, Tschopp J.

Science. 1996 Nov 22;274(5291):1363-6.

PMID:
8910274
8.
9.

Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice.

Lau HT, Yu M, Fontana A, Stoeckert CJ Jr.

Science. 1996 Jul 5;273(5271):109-12.

PMID:
8658177
10.

Fas ligand in human serum.

Tanaka M, Suda T, Haze K, Nakamura N, Sato K, Kimura F, Motoyoshi K, Mizuki M, Tagawa S, Ohga S, Hatake K, Drummond AH, Nagata S.

Nat Med. 1996 Mar;2(3):317-22.

PMID:
8612231
11.

Gene therapy for vascular smooth muscle cell proliferation after arterial injury.

Ohno T, Gordon D, San H, Pompili VJ, Imperiale MJ, Nabel GJ, Nabel EG.

Science. 1994 Aug 5;265(5173):781-4.

PMID:
8047883
12.

Lethal effect of the anti-Fas antibody in mice.

Ogasawara J, Watanabe-Fukunaga R, Adachi M, Matsuzawa A, Kasugai T, Kitamura Y, Itoh N, Suda T, Nagata S.

Nature. 1993 Aug 26;364(6440):806-9. Erratum in: Nature 1993 Oct 7;365(6446):568.

PMID:
7689176
13.

Clearance of adenovirus-infected hepatocytes by MHC class I-restricted CD4+ CTLs in vivo.

Yang Y, Wilson JM.

J Immunol. 1995 Sep 1;155(5):2564-70.

PMID:
7650386
14.

A role for CD95 ligand in preventing graft rejection.

Bellgrau D, Gold D, Selawry H, Moore J, Franzusoff A, Duke RC.

Nature. 1995 Oct 19;377(6550):630-2. Erratum in: Nature 1998 Jul 9;394(6689):133.

PMID:
7566174
15.

The Fas death factor.

Nagata S, Golstein P.

Science. 1995 Mar 10;267(5203):1449-56. Review.

PMID:
7533326
16.

Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation.

Ju ST, Panka DJ, Cui H, Ettinger R, el-Khatib M, Sherr DH, Stanger BZ, Marshak-Rothstein A.

Nature. 1995 Feb 2;373(6513):444-8.

PMID:
7530337
17.

Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas.

Brunner T, Mogil RJ, LaFace D, Yoo NJ, Mahboubi A, Echeverri F, Martin SJ, Force WR, Lynch DH, Ware CF, et al.

Nature. 1995 Feb 2;373(6513):441-4.

PMID:
7530336
18.

Autocrine T-cell suicide mediated by APO-1/(Fas/CD95)

Dhein J, Walczak H, Bäumler C, Debatin KM, Krammer PH.

Nature. 1995 Feb 2;373(6513):438-41.

PMID:
7530335
19.

Fas ligation triggers apoptosis in macrophages but not endothelial cells.

Richardson BC, Lalwani ND, Johnson KJ, Marks RM.

Eur J Immunol. 1994 Nov;24(11):2640-5.

20.

Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family.

Suda T, Takahashi T, Golstein P, Nagata S.

Cell. 1993 Dec 17;75(6):1169-78.

PMID:
7505205

Supplemental Content

Support Center